Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomasDecember 10, 2017Aggressive LymphomasCellular TherapyIndolent LymphomaB Cell Lymphoma
CAR T-cells gain ground against hematologic cancersNovember 22, 2017Aggressive LymphomasMultiple Myeloma
Rituximab key to survival after transplant for mantle cell lymphomaNovember 16, 2017Mantle Cell LymphomaAggressive Lymphomas
NCI-MATCH: Nivolumab shows promising activity in noncolorectal cancersNovember 15, 2017Aggressive Lymphomas
Event-free survival at 24 months predicts outcomes in peripheral T-cell lymphomasNovember 2, 2017Aggressive Lymphomas
Nivolumab linked to CNS disorder in case reportNovember 2, 2017Patient & Survivor CareAggressive Lymphomas
Rituximab improves salvage in elderly B-cell lymphoma patientsOctober 23, 2017Aggressive LymphomasB Cell Lymphoma
Adding bortezomib to R-CHOP didn’t improve survival in diffuse large B-cell lymphomaSeptember 29, 2017Aggressive LymphomasB Cell Lymphoma
FDA grants accelerated approval to copanlisib for relapsed follicular lymphomaSeptember 20, 2017Aggressive Lymphomas
Biosimilar matches rituximab in large follicular lymphoma trialSeptember 12, 2017Aggressive Lymphomas
